Barclays views the recent pullback in shares of Relay Therapeutics (RLAY) as a buying opportunity. The firm says Relay stands out in its coverage as having the greatest upside and exposure to artificial intelligence-driven drug discovery. Barclays likes the risk/reward of Relay with the stock trading at 0.6-times cash, a cash runway into the second half of 2025, and a “derisked catalyst path.” The firm has an Overweight rating on the name with a $17 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics: Promising Clinical Trials and Strategic Positioning Justify Buy Rating
- Buy Rating for Relay Therapeutics Amid Strategic Clinical Progress and Resource Optimization
- Relay Therapeutics price target lowered to $12 from $21 at Citizens JMP
- Buy Rating for Relay Therapeutics Driven by Strategic Advancements and Promising Clinical Trial Developments
- Relay Therapeutics Reports 2024 Financial Results and Progress